

J PÃ©rez Fidalgo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889217/publications.pdf>

Version: 2024-02-01

89
papers

3,809
citations

185998

28
h-index

128067

60
g-index

95
all docs

95
docs citations

95
times ranked

7414
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. <i>Gynecologic Oncology</i> , 2022, 164, 406-414.	0.6	4
2	Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1142.	1.8	5
3	Associations between Taste Perception Profiles and Empirically Derived Dietary Patterns: An Exploratory Analysis among Older Adults with Metabolic Syndrome. <i>Nutrients</i> , 2022, 14, 142.	1.7	5
4	Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network. <i>Cancers</i> , 2022, 14, 1965.	1.7	1
5	A phase III trial of alpelisib+trastuzumab +fulvestrant versus trastuzumab+ chemotherapy in HER2+ PIK3CA-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349.	1.1	15
6	SEOM clinical guideline in ovarian cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 961-968.	1.2	22
7	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
8	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	2.2	19
9	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	2.0	37
10	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
11	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
12	Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
13	Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk. <i>Nutrients</i> , 2020, 12, 3323.	1.7	4
14	Aurora kinases in ovarian cancer. <i>ESMO Open</i> , 2020, 5, e000718.	2.0	15
15	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1712-1712.	0.7	36
16	NOTCH signalling in ovarian cancer angiogenesis. <i>Annals of Translational Medicine</i> , 2020, 8, 1705-1705.	0.7	24
17	Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified breast cancer models: A new step towards precision medicine. , 2020, , .		0
18	Candidate Gene and Genome-Wide Association Studies for Circulating Leptin Levels Reveal Population and Sex-Specific Associations in High Cardiovascular Risk Mediterranean Subjects. <i>Nutrients</i> , 2019, 11, 2751.	1.7	16

#	ARTICLE	IF	CITATIONS
19	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisis for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
20	GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. <i>Future Science OA</i> , 2019, 5, FSO370.	0.9	6
21	BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. <i>Annals of Oncology</i> , 2019, 30, 774-780.	0.6	57
22	A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. <i>Clinical Epigenetics</i> , 2019, 11, 33.	1.8	39
23	Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2606-2606.	0.8	2
24	Phase I of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3089-3089.	0.8	0
25	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	5.1	98
26	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 2517-2529.	3.2	26
27	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2050-2059.	3.2	96
28	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285.	1.2	5
29	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	0.8	43
30	In the literature: June 2018. <i>ESMO Open</i> , 2018, 3, e000401.	2.0	0
31	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 285-298.	1.1	37
32	DNA methylation as an epigenetic signature predictive of response to neoadjuvant treatment in TNBC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12658-e12658.	0.8	1
33	A phase II clinical trial to analyze olaparib response in patients with <i>BRCA1</i> and/or <i>BRCA</i>2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1114-TPS1114.	0.8	3
34	A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trialâ€”A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5610-TPS5610.	0.8	0
35	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	7.2	449
36	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113.	7.7	136

#	ARTICLE	IF	CITATIONS
37	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	0.8	240
38	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2555-2555.	0.8	2
39	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 69-77.	1.1	20
40	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	2.0	41
41	Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 530-530.	0.8	4
42	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	0.8	11
43	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2548-2548.	0.8	0
44	Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 1053.	1.0	6
45	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0130543.	1.1	9
46	Deregulation of <i>ARID1A</i> , <i>CDH1</i> , <i>cMET</i> and <i>PIK3CA</i> and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015, 6, 26935-26945.	0.8	35
47	Abstract CT331: "BEECH", a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s. , 2015, , .		2
48	DNA methylation signature to identify treatment response in triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1079-1079.	0.8	1
49	A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2500-2500.	0.8	6
50	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 669-669.	0.8	11
51	Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+ breast cancer cells with de novo resistance to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11592-e11592.	0.8	1
52	Zoledronic acid in the treatment of metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 1-7.	0.7	13
53	Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	3.2	529
54	Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: A prospective study. <i>Palliative Medicine</i> , 2014, 28, 326-334.	1.3	37

#	ARTICLE	IF	CITATIONS
55	Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 814-822.	1.2	7
56	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 507-515.	1.1	60
57	<i>Breast Cancer Stem Cells.</i> , 2014, , 107-126.		0
58	MicroRNA profile in very young women with breast cancer. <i>BMC Cancer</i> , 2014, 14, 529.	1.1	56
59	Subcutaneous trastuzumab: drug development and current position. <i>Clinical and Translational Oncology</i> , 2014, 16, 859-864.	1.2	2
60	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1382-1389.	1.9	104
61	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 60-67.	3.4	150
62	An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. <i>Breast</i> , 2013, 22, 974-979.	0.9	7
63	Reply to 'Comment on: management of chemotherapy extravasation: ESMO's clinical practice guidelines'. <i>Annals of Oncology</i> , 2013, 24, 1129-1130.	0.6	1
64	Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.. <i>Molecular Cancer Therapeutics</i> , 2013, 12, C252-C252.	1.9	16
65	Nova era en el combat contra el cÃ¡ncer: evoluciÃ³ i cÃ¡ncer: progrÃ©s i tractament de tumors. MÃ³de Revista De DifusiÃ³ De La InvestigaciÃ³ De La Universitat De ValÃ©ncia, 2013, .	0.0	0
66	Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4764-4774.	3.2	132
67	Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. <i>Cancer Treatment Reviews</i> , 2012, 38, 698-707.	3.4	466
68	Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?. <i>European Journal of Surgical Oncology</i> , 2012, 38, 643-644.	0.5	1
69	Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. <i>Cancer Research</i> , 2012, 72, CT-02-CT-02.	0.4	10
70	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3637-TPS3637.	0.8	3
71	Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14589-e14589.	0.8	0
72	Retrospective analysis of the use of GCSF and its impact on dose-response effect for anthracycline plus taxane-based schedules in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11523-e11523.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. Journal of Clinical Oncology, 2012, 30, 1074-1074.	0.8	0
74	Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?. Breast, 2011, 20, 548-554.	0.9	53
75	First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.. Journal of Clinical Oncology, 2011, 29, 3022-3022.	0.8	13
76	Switching to aromatase inhibitor (AI) after tamoxifen in premenopausal patients with chemotherapy-induced amenorrhea (CIA) after early breast cancer treatment.. Journal of Clinical Oncology, 2011, 29, e11099-e11099.	0.8	0
77	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Research and Treatment, 2010, 120, 245-251.	1.1	53
78	Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Research and Treatment, 2009, 114, 479-484.	1.1	154
79	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clinical and Translational Oncology, 2009, 11, 787-798.	1.2	33
80	Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain). Clinical and Translational Oncology, 2008, 10, 745-752.	1.2	7
81	Parotid gland metastasis of a breast cancer. Clinical and Translational Oncology, 2007, 9, 264-265.	1.2	19
82	Primary carcinoid tumour of the pancreas. Clinical and Translational Oncology, 2006, 8, 54-56.	1.2	3
83	Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer. Clinical and Translational Oncology, 2005, 7, 23-28.	1.2	4
84	High grade gliomas. Multidisciplinary treatment with radiotherapy and concurrent carmustine after surgery. Clinical and Translational Oncology, 2004, 6, 207-211.	1.2	1
85	High risk Ewing's sarcomas. Effectiveness and toxicity of a regimen designed for children and used in adults. Clinical and Translational Oncology, 2004, 6, 165-169.	1.2	2
86	Analysis of Clinical Prognostic Factors for Survival and Time to Progression in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracilâ€”Based Chemotherapy. Clinical Colorectal Cancer, 2003, 2, 231-234.	1.0	29
87	Primitive neuroectodermal kidney tumor. Medical and Pediatric Oncology, 2002, 38, 145-145.	1.0	4
88	Non-Hodgkin's Lymphoma in Older People: Age Is Not Always an Adverse Prognostic Factor. Journal of the American Geriatrics Society, 2002, 50, 1911-1912.	1.3	1
89	Pulmonary Fibrosis Induced by Cyclophosphamide. Annals of Pharmacotherapy, 2001, 35, 894-897.	0.9	52